跳至主要内容
临床试验/NL-OMON35885
NL-OMON35885撤回2 期

An Investigation of the Effect of Long-Term Electrical Stimulation on Lower Esophageal Sphincter (LES) Pressure and Esophageal Acid Exposure in Patients with Gastroesophageal Reflux Disease (GERD) - CS005, EndoStim Inc., Electrical Stimulation

EndoStim, Inc.0 个研究点目标入组 8 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
撤回
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • a. Subject is between 21 - 65 years of age.
  • b. Subject has a history of heartburn, regurgitation or both for >6 month prompting physician
  • recommendation of continual daily use of PPI before study entry. Baseline GERD HRQL
  • heartburn score of >= 20 off PPI assessed during the run in phase.
  • c. Subject has an American Society of Anesthesiologists (ASA) Physical Status Classification I or
  • II (or comparable local classification if any).
  • d. Subject has demonstrated satisfactory symptomatic response to a previous course of GERD
  • therapy (>= 2 weeks). GERD HRQL heartburn score improvement of > 10 on therapy as
  • assessed within 6 weeks of enrollment.
  • e. Subject has exhibited excessive lower esophageal acid exposure during 24-hour pH-metry of
  • antisecretory therapy performed within 6 months of enrollment; pH < 4 for > 5% of total time or >
  • 3% of supine time.
  • f. Subject has a resting LES end expiratory pressure > 5mm Hg and < 15 mm Hg on a high
  • resolution manometry within 6 months of enrollment.
  • g. Subject has esophagitis <= Grade C (LA classification) on upper endoscopy within 6 months of
  • enrollment.
  • h. Subject has esophageal body contraction amplitude > 30 mmHg for >70% of swallows and >
  • 50% peristaltic contractions on high resolution manometry.
  • i. Subject has signed the informed consent form.

排除标准

  • a. Subject has any non-GERD esophageal motility disorders.
  • b. Subject has gastroparesis.
  • c. Subject has any significant multisystem diseases.
  • d. Subject has an autoimmune or a connective tissue disorder (e.g. scleroderma,
  • dematomyositis, Calcinosis-Raynaud*s-Esophagus Sclerodactyly Syndrome (CREST),
  • Sjogren*s Syndrome, Sharp*s Syndrome) requiring therapy in the preceding 2 years.
  • e. Subject has Barrett*s epithelium (> M2; >C1) or any grade of dysplasia.
  • f. Subject has a hiatal hernia larger than 3 cm.
  • g. Subject has a body mass index (BMI) greater than 35 kg/m2.
  • h. Subject has Type 1 diabetes mellitus
  • i. Subject has uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c >9.5 in the
  • previous 6 months, or has T2DM for > 10 years.
  • j. Subject has a history of suspected or confirmed esophageal or gastric cancer.
  • k. Subject has esophageal or gastric varices.
  • l. Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease.
  • m. Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).
  • n. Subject requires chronic anticoagulant therapy.
  • o. Subject has dysphagia or esophageal peptic stricture, excluding Schatzki*s ring.
  • p. Subject is pregnant or intends to become pregnant during the trial period.
  • q. Subject is currently enrolled in other potentially confounding research.
  • r. History of any malignancy in the last 2 years.
  • s. History of previous esophageal or gastric surgery, including nissen fundoplication.
  • t. Subject has any condition that, at the discretion of the investigator or sponsor, would preclude
  • participation in the trial.

研究者

相似试验